Success Metrics

Clinical Success Rate
63.6%

Based on 7 completed trials

Completion Rate
64%(7/11)
Active Trials
9(27%)
Results Posted
14%(1 trials)
Terminated
4(12%)

Phase Distribution

Ph not_applicable
5
15%
Ph phase_1
1
3%
Ph early_phase_1
1
3%
Ph phase_2
13
39%
Ph phase_3
9
27%

Phase Distribution

2

Early Stage

13

Mid Stage

9

Late Stage

Phase Distribution29 total trials
Early Phase 1First-in-human
1(3.4%)
Phase 1Safety & dosage
1(3.4%)
Phase 2Efficacy & side effects
13(44.8%)
Phase 3Large-scale testing
9(31.0%)
N/ANon-phased studies
5(17.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

58.3%

7 of 12 finished

Non-Completion Rate

41.7%

5 ended early

Currently Active

9

trials recruiting

Total Trials

33

all time

Status Distribution
Active(12)
Completed(7)
Terminated(5)
Other(9)

Detailed Status

unknown9
Completed7
Recruiting5
Active, not recruiting4
Terminated4
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
33
Active
9
Success Rate
63.6%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (3.4%)
Phase 11 (3.4%)
Phase 213 (44.8%)
Phase 39 (31.0%)
N/A5 (17.2%)

Trials by Status

completed721%
not_yet_recruiting39%
withdrawn13%
recruiting515%
unknown927%
active_not_recruiting412%
terminated412%

Recent Activity

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more
NCT05430035Early Phase 1

Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma

Recruiting
NCT03842982Phase 3

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

Active Not Recruiting
NCT05316181Phase 3

CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)

Active Not Recruiting
NCT07304258Phase 2

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Not Yet Recruiting
NCT06427252Phase 2

The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM

Active Not Recruiting
NCT01376752Phase 3

Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment

Active Not Recruiting
NCT06685887Phase 2

A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

Recruiting
NCT03422432Not Applicable

Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases

Completed
NCT06760858

A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer

Recruiting
NCT02040142Phase 2

HIPEC for Peritoneal Carcinomatosis

Completed
NCT03514888Not Applicable

HIPEC After Radical Cystectomy for High Risk Bladder Cancer

Completed
NCT03275194Phase 2

HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy

Recruiting
NCT05265117

The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study

Unknown
NCT03321188Phase 2

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

Unknown
NCT05300945Phase 2

HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy

Not Yet Recruiting
NCT03604653

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

Completed
NCT05246020Phase 2

Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial)

Unknown
NCT05095467Phase 2

HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction

Not Yet Recruiting
NCT02158988Phase 3

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis

Completed
NCT03230240

Immunologic Profile of Peritoneal Cancer

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
33